Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus

AIMS: To evaluate the immunogenicity of LY2963016 insulin glargine (LY IGlar) versus originator insulin glargine (IGlar [Lantus®]) in Chinese patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: ABES and ABET were prospective, randomized, active control, open‐label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Weimin, Song, Xiang, Lou, Ying, Du, Liying, Zhu, Dalong, Zhou, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314964/
https://www.ncbi.nlm.nih.gov/pubmed/35187770
http://dx.doi.org/10.1111/dom.14674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314964/
https://www.ncbi.nlm.nih.gov/pubmed/35187770
http://dx.doi.org/10.1111/dom.14674

Ejemplares similares